Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 20, 2013

View Archived Issues

Quantitative, non-invasive, magnetic resonance imaging of tumor metabolism in vivo

Identification of a novel clinical biomarker for a specific subset of patients with breast cancer

Phase I clinical evaluation of a sporozoite-based vaccine for immunization against malaria

LIDDS reports data from second phase IIa study of Liproca Depot

Researchers highlight the relevance of BAP1 mutations in melanoma

Retrophin to exclusively negotiate development rights for autism and schizophrenia treatment

Retrophin reports RE-024 preclinical results

FDA approves GSK's FluLaval Quadrivalent influenza virus vaccine

Australian government provides grant to Aeras for tuberculosis vaccine

New MGAT2 inhibitors for hypertriglyceridemia presented by Eli Lilly

Taiho Pharmaceutical designs novel agents for urinary incontinence

Selexys commences with SUSTAIN phase II trial

Roche and Genentech disclose new MEKKK4 inhibitors

Actelion synthesizes new chemokine CXCR3 receptor modulators

French authorities grant market access to Pixuvri for aggressive non-Hodgkin's lymphoma

Toyama Chemical Co. presents novel products for HIV infection

Tau Therapeutics collaborator receives grant for glioblastoma reserach

BIND Therapeutics initiates dosing in phase II PSMA-targeting study

GenSpera raises funds for G-202 development

to-BBB to proceed to phase IIa 2B3-101 study

GTx' POWER trials fail to meet primary endpoints

Wanbang Pharma to develop Sirona Biochem's SGLT2 inhibitor in China

FDA approves Trokendi XR launch

Japanese researchers divulge new tubulin polymerization inhibitors

Japanese authorities approve Bayer's Stivarga for GIST

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026